TOP TIERMARKET NEWSWIRE

News & sentiment

CELCUITY INC (CELC) — News & AI sentiment

CELCUITY INC (CELC) news roundup. 10 stories in the past week, 26 over 30 days. Average 30-day sentiment is 61.7/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

10

avg sentiment 64.6/100

30d stories

26

avg sentiment 61.7/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

CELC news in the last 24 hours, 7 days, 30 days and 90 days

How much CELC coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	CELC stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	10	64.6/100	CELC headlines →
Last 30 days	26	61.7/100	CELC headlines →
Last 90 days	61	56.6/100	CELC headlines →

Latest stories on CELC

Celcuity says Revtorpyk boosts progression-free survival in breast cancer

Seeking Alpha74 · bullishproduct/pr

2d ago

Celcuity announces results from PIK3CA cohort of Phase 3 VIKTORIA-1

The Fly58 · neutralproduct/pr

3d ago

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

StockTitan64 · neutralproduct/pr

4d ago

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

GlobeNewswire64 · neutralproduct/pr

4d ago

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

Business Insider64 · neutralproduct/pr

4d ago

Celcuity announces updated results from gedatolisib trial at ESMO

The Fly63 · neutralproduct/pr

5d ago

Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026

Business Insider64 · neutralproduct/pr

5d ago

Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026

GlobeNewswire64 · neutralproduct/pr

5d ago

Cantor sees ‘credible path to multi-billion-dollar peak sales’ for Celcuity

Investing.com Markets68 · bullishanalyst

6d ago

Cantor Fitzgerald initiates Celcuity stock with overweight rating

Investing.com Analyst Ratings63 · neutralanalyst

6d ago

Celcuity stock price target raised to $145 by TD Cowen on uptake

Investing.com Analyst Ratings64 · neutralanalyst

Oct 21

Citizens reiterates Celcuity stock rating on ESMO data presentation

Investing.com Analyst Ratings52 · neutralanalyst

Oct 19

Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026

GlobeNewswire63 · neutralproduct/pr

Oct 5

Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026

Business Insider63 · neutralproduct/pr

Oct 5

Celcuity adds seasoned director amid oncology commercialization push

TipRanks56 · neutralgeneral

Oct 2

Celcuity appoints Gryska to Board of Directors

The Fly55 · neutralgeneral

Oct 2

Celcuity Inc. (CELC) files 8-K

SEC 8-K50 · neutralgeneral

Oct 2

Celcuity Appoints David Gryska To Its Board Of Directors

Business Insider50 · neutralgeneral

Oct 2

Celcuity Appoints David Gryska To Its Board Of Directors

GlobeNewswire50 · neutralgeneral

Oct 2

Why Celcuity Stock Was a Winner on Wednesday

The Motley Fool73 · bullishproduct/pr

Sep 30

CELC Launches REVTORPYK in the U.S. for HR+/HER2- Advanced Breast Cancer Without PIK3CA Mutation September 30, 2026

MarketChameleon67 · bullishproduct/pr

Sep 30

Celcuity says REVTORPYK is now commercially available in the U.S., expanding access after July FDA approval September 30, 2026

MarketChameleon73 · bullishproduct/pr

Sep 30

Celcuity announces REVTORPYK is now commercially available in U.S.

The Fly63 · neutralproduct/pr

Sep 30

Celcuity Inc. (CELC) files 8-K

SEC 8-K50 · neutralgeneral

Sep 30

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

GlobeNewswire67 · bullishproduct/pr

Sep 30

Open CELC in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →